CN117965692A - 通过基于生物流体的无细胞dna（cfdna）测定评价器官损伤状态的基于免疫探针的新方法 - Google Patents

通过基于生物流体的无细胞dna（cfdna）测定评价器官损伤状态的基于免疫探针的新方法 Download PDF

Info

Publication number
CN117965692A
CN117965692A CN202410041779.5A CN202410041779A CN117965692A CN 117965692 A CN117965692 A CN 117965692A CN 202410041779 A CN202410041779 A CN 202410041779A CN 117965692 A CN117965692 A CN 117965692A
Authority
CN
China
Prior art keywords
cfdna
reaction mixture
nucleic acid
kidney
acid probe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410041779.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·M·萨尔沃
T·K·西格德尔
杨心民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN117965692A publication Critical patent/CN117965692A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G01N33/6839—Total protein determination, e.g. albumin in urine involving dyes, e.g. Coomassie blue, bromcresol green
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202410041779.5A 2016-08-17 2017-08-17 通过基于生物流体的无细胞dna（cfdna）测定评价器官损伤状态的基于免疫探针的新方法 Pending CN117965692A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662376299P 2016-08-17 2016-08-17
US62/376,299 2016-08-17
PCT/US2017/047372 WO2018035340A1 (en) 2016-08-17 2017-08-17 A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay
CN201780063968.0A CN109890977A (zh) 2016-08-17 2017-08-17 通过基于生物流体的无细胞dna(cfdna)测定评价器官损伤状态的基于免疫探针的新方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780063968.0A Division CN109890977A (zh) 2016-08-17 2017-08-17 通过基于生物流体的无细胞dna(cfdna)测定评价器官损伤状态的基于免疫探针的新方法

Publications (1)

Publication Number Publication Date
CN117965692A true CN117965692A (zh) 2024-05-03

Family

ID=61197090

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410041779.5A Pending CN117965692A (zh) 2016-08-17 2017-08-17 通过基于生物流体的无细胞dna（cfdna）测定评价器官损伤状态的基于免疫探针的新方法
CN201780063968.0A Pending CN109890977A (zh) 2016-08-17 2017-08-17 通过基于生物流体的无细胞dna(cfdna)测定评价器官损伤状态的基于免疫探针的新方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780063968.0A Pending CN109890977A (zh) 2016-08-17 2017-08-17 通过基于生物流体的无细胞dna(cfdna)测定评价器官损伤状态的基于免疫探针的新方法

Country Status (7)

Country Link
US (7) US11124824B2 (enExample)
EP (2) EP3845665A1 (enExample)
JP (1) JP7109424B2 (enExample)
CN (2) CN117965692A (enExample)
AU (3) AU2017313138B2 (enExample)
CA (2) CA3311735A1 (enExample)
WO (1) WO2018035340A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US12655483B2 (en) 2010-05-18 2026-06-16 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
CN105190656B (zh) 2013-01-17 2018-01-16 佩索纳里斯公司 用于遗传分析的方法和系统
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US10125399B2 (en) 2014-10-30 2018-11-13 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
EP4428863A3 (en) 2015-05-11 2024-12-11 Natera, Inc. Methods and compositions for determining ploidy
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
JP7280044B2 (ja) 2016-04-15 2023-05-23 ナテラ， インコーポレイテッド 肺癌の検出方法
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
EP3491381B1 (en) 2016-07-29 2025-09-24 Streck LLC Suspension composition for hematology analysis control
EP3845665A1 (en) 2016-08-17 2021-07-07 The Regents Of The University Of California A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
JP7293244B2 (ja) 2017-10-19 2023-06-19 ストレック， インコーポレイテッド 溶血、凝固調節および細胞外小胞の安定化のための組成物
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
EP3737773B1 (en) 2018-01-12 2023-04-12 Natera, Inc. Novel primers and uses thereof
DK3781714T3 (da) 2018-04-14 2026-03-30 Natera Inc Fremgangsmåder til cancerpåvisning og -overvågning ved personlig påvisning af cirkulerende tumor-dna
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
EP3905881A1 (en) * 2019-01-04 2021-11-10 QIAGEN GmbH Urine stabilization
KR20260023068A (ko) * 2019-01-24 2026-02-20 일루미나, 인코포레이티드 장기 건강 및 질환을 모니터링하기 위한 방법 및 시스템
JP7470787B2 (ja) 2019-11-05 2024-04-18 パーソナリス，インコーポレイティド 単一試料からの腫瘍純度の推定
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
WO2022133159A1 (en) * 2020-12-17 2022-06-23 Nephrosant, Inc. Kits for stabilization of urine samples
US20240279720A1 (en) * 2021-07-23 2024-08-22 Georgetown University Use of genetic and epigenetic markers to detect cell death
WO2023059654A1 (en) 2021-10-05 2023-04-13 Personalis, Inc. Customized assays for personalized cancer monitoring
US20250046451A1 (en) * 2021-11-30 2025-02-06 Kidneymetrix, Inc. Generative Adversarial Network for Urine Biomarkers
JP2025520693A (ja) * 2022-06-21 2025-07-03 ガーヴァン インスティテュート オブ メディカル リサーチ 細胞損傷の検出
EP4587588A1 (en) 2022-09-16 2025-07-23 Illumina, Inc. Nanoparticle with polynucleotide binding site and method of making thereof
EP4788836A1 (en) * 2023-10-06 2026-08-12 Neutrolis, Inc. Biomarker and precision therapy for inflammatory disease
WO2026006629A1 (en) 2024-06-27 2026-01-02 Personalis, Inc. System and method for management of compressed sequencing files

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0821041B2 (ja) 1988-06-01 1996-03-04 横河電機株式会社 プリント基板ｃａｄの部品シンボル作成方法
US5849517A (en) 1991-05-08 1998-12-15 Streck Laboratories, Inc. Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same
JPH0821041A (ja) 1994-07-07 1996-01-23 Ig Tech Res Inc 瓦棒葺屋根の改修構造
WO1996021041A1 (en) 1994-12-29 1996-07-11 Eiken Kagaku Kabushiki Kaisha Method of cell detection
JPH1021041A (ja) * 1996-06-28 1998-01-23 Matsushita Electric Ind Co Ltd 操作パネル
US7537889B2 (en) * 2003-09-30 2009-05-26 Life Genetics Lab, Llc. Assay for quantitation of human DNA using Alu elements
WO2006128192A2 (en) * 2005-05-27 2006-11-30 John Wayne Cancer Institute Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
WO2009042457A1 (en) 2007-09-21 2009-04-02 Streck, Inc. Nucleic acid isolation in preserved whole blood
JP2010017178A (ja) 2008-06-11 2010-01-28 Sumitomo Chemical Co Ltd Ｄｎａを定量又は検出する方法
US8304187B2 (en) 2009-02-18 2012-11-06 Streck, Inc. Preservation of cell-free RNA in blood samples
US8404444B2 (en) 2009-02-25 2013-03-26 Diacarta Llc Method for predicting the level of damage to cells by measuring free circulating Alu nucleic acid
WO2011014741A1 (en) 2009-07-31 2011-02-03 Artemis Health, Inc. Methods and compositions for cell stabilization
US20110111410A1 (en) * 2009-11-09 2011-05-12 Streck, Inc. Stabilization of rna in intact cells within a blood sample
MX342967B (es) * 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
WO2012108538A1 (ja) * 2011-02-10 2012-08-16 国立大学法人 長崎大学 急性肺損傷診断方法
JP5214042B2 (ja) 2012-02-03 2013-06-19 アンリツ株式会社 光素子パッケージの製造方法
US10472679B2 (en) * 2012-05-15 2019-11-12 Cornell University Non-invasive method of diagnosing renal fibrosis
US10233508B2 (en) * 2012-08-21 2019-03-19 Qiagen Gmbh Virus particle stabilisation and method for isolating viral nucleic acids
EP2888363B1 (en) 2012-08-21 2018-06-06 Qiagen GmbH Method for isolating nucleic acids from a formaldehyde releaser stabilized sample
WO2014074501A1 (en) * 2012-11-06 2014-05-15 Quest Diagnostics Investments Incorporated Molecular markers for diagnosis of acute cellular rejection and acute tubular necrosis
HK1217733A1 (zh) 2013-03-15 2017-01-20 Immucor Gti Diagnostics, Inc. 使用尿游离dna评估肾状态的方法和组合物
US20160281133A1 (en) 2013-03-18 2016-09-29 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
CA2922746A1 (en) * 2013-09-06 2015-03-12 Immucor Gti Diagnostics, Inc. Compositions and methods for diagnosis and prediction of solid organ graft rejection
SI4026917T1 (sl) * 2014-04-14 2024-05-31 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Metoda in komplet za določanje smrti celic ali tkiva oz. izvora DNK tkiva ali celice z analizo metilacije DNK
ES2692393T3 (es) 2014-04-24 2018-12-03 Euroclone Spa Método de diagnóstico in vitro para cáncer por medio de ADN circulante libre de células
SG11201700146QA (en) 2014-07-09 2017-02-27 Exosome Diagnostics Inc Methods for isolating microvesicles and extracting nucleic acids from biological samples
WO2018031903A1 (en) * 2016-08-12 2018-02-15 Streck, Inc. Molecular reference controls
EP3845665A1 (en) 2016-08-17 2021-07-07 The Regents Of The University Of California A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay

Also Published As

Publication number Publication date
US11926868B2 (en) 2024-03-12
WO2018035340A1 (en) 2018-02-22
EP3845665A1 (en) 2021-07-07
AU2017313138A1 (en) 2019-03-07
US20210024988A1 (en) 2021-01-28
AU2024202089C1 (en) 2026-03-26
JP7109424B2 (ja) 2022-07-29
CN109890977A (zh) 2019-06-14
AU2024202089C8 (en) 2026-05-07
JP2019528063A (ja) 2019-10-10
US20220033892A1 (en) 2022-02-03
CA3033650A1 (en) 2018-02-22
US20190211385A1 (en) 2019-07-11
US10982272B2 (en) 2021-04-20
US20200032331A1 (en) 2020-01-30
EP3500687A1 (en) 2019-06-26
AU2026201931A1 (en) 2026-04-02
US11753680B2 (en) 2023-09-12
US20210340610A1 (en) 2021-11-04
EP3500687A4 (en) 2020-07-29
US11505822B2 (en) 2022-11-22
AU2017313138B2 (en) 2024-01-04
CA3311735A1 (en) 2026-06-21
US10995368B2 (en) 2021-05-04
AU2024202089A1 (en) 2024-05-02
US20220333182A1 (en) 2022-10-20
US11124824B2 (en) 2021-09-21
AU2024202089B2 (en) 2025-12-18
US20240309440A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
US11753680B2 (en) Methods of preparing a biofluid sample for detection of kidney injury
US20100190656A1 (en) Breast Cancer Specific Markers and Methods of Use
US9758828B2 (en) Methods to detect, treat and prevent acute cellular rejection in kidney allografts
CN107541563B (zh) 一种用于早期诊断、预测脓毒血症并发急性肾损伤的分子标记物、试剂盒及应用
CA2902006A1 (en) Methods and compositions for assessing renal status using urine cell free dna
JP5629894B2 (ja) 甲状腺乳頭癌を診断するための新規のマーカー
US20180251844A1 (en) Host dna as a biomarker of crohn's disease
JP2018517775A (ja) クローン病を治療する方法
RU2463354C1 (ru) Способ диагностики рака мочевого пузыря с помощью онкомаркера tfdp1 (варианты) и набор для его осуществления
KR101874632B1 (ko) 크론병에 대한 바이오마커 및 이를 이용한 크론병의 진단
CN115803450A (zh) 特应性皮炎的重症度的检测方法
CN113403382B (zh) Ube2f在诊治股骨头坏死中的应用
RU2468088C1 (ru) Способ оценки эффективности терапии рака мочевого пузыря человека методом иммуноферментного анализа
RU2470301C2 (ru) Способ диагностики рака мочевого пузыря с помощью онкомаркера kifc1 (варианты) и набор для его осуществления
HK40010652A (en) A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay
CN107541564B (zh) 分子标记物tcons_00016233、试剂盒及应用
RU2469098C2 (ru) Способ оценки эффективности терапии рака мочевого пузыря человека методом пцр в режиме реального времени и набор для его осуществления
CN112760372A (zh) 心肌梗死差异表达基因及其应用
RU2468372C1 (ru) Способ оценки эффективности терапии рака мочевого пузыря с помощью онкомаркера nusap1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination